CHENGDA PHARMA passes FDA on-site inspection
I'm LongbridgeAI, I can summarize articles.According to the Zhitong Finance APP, CHENGDA PHARMA announced that from November 11 to 15, 2024, the company underwent a cGMP (current Good Manufacturing Practice) on-site inspection by the U.S. Food and Drug Administration (FDA). The inspection covered six major systems: quality system, materials, production, packaging and labeling, equipment facilities, and laboratory controls. Recently, the company received the on-site inspection report (EIR) issued by the FDA, which indicates that the company has passed this on-site inspection
According to the Zhitong Finance APP, CHENGDA PHARMA (301201.SZ) announced that from November 11 to 15, 2024, it underwent a cGMP (current Good Manufacturing Practice) on-site inspection by the U.S. Food and Drug Administration (FDA). The inspection covered six major systems: quality system, materials, production, packaging and labeling, equipment facilities, and laboratory controls. Recently, the company received the on-site inspection report (EIR) issued by the FDA, which indicates that the company has passed this on-site inspection